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The issue of predicting treatment response and identifying, in advance, which patient
will profit from treating obsessive-compulsive disorder (OCD) seems to be an elusive
goal. This prospective study investigated brain electric activity [using Low-Resolution
Brain Electromagnetic Tomography (LORETA)] for the purpose of predicting response
to treatment. Forty-one unmedicated patients with a DSM-IV diagnosis of OCD were
included. A resting 32-channel EEG was obtained from each participant before and after
10 weeks of standardized treatment with sertraline and behavioral therapy. LORETA
was used to localize the sources of brain electrical activity. At week 10, patients were
divided into responders and non-responders (according to a reduction of symptom
severity >50% on the Y-BOCS). LORETA analysis revealed that at baseline responders
showed compared to non-responders a significantly lower brain electric activity within the
beta 1 (t = 2.86, p < 0.05), 2 (t = 2.81, p < 0.05), and 3 (t = 2.76, p < 0.05) frequency
bands and ROI analysis confirmed a reduced activity in alpha 2 (t = 2.06, p < 0.05)
in the anterior cingulate cortex (ACC). When baseline LORETA data were compared to
follow-up data, the analysis showed in the responder group a significantly lower brain
electrical resting activity in the beta 1 (t = 3.17. p < 0.05) and beta 3 (t = 3.11. p < 0.05)
frequency bands and equally for the ROI analysis of the orbitofrontal cortex (OFC) in
the alpha 2 (t = 2.15. p < 0.05) frequency band. In the group of non-responders the
opposite results were found. In addition, a positive correlation between frequency alpha
2 (rho = 0.40, p = 0.010), beta 3 (rho = 0.42, p = 0.006), delta (rho = 0.33, p = 0.038),
theta (rho = 0.34, p = 0.031), alpha 1 (rho = 0.38, p = 0.015), and beta1 (rho = 0.34,
p = 0.028) of the OFC and the bands delta (rho= 0.33, p = 0.035), alpha 1 (rho = 0.36,
p = 0.019), alpha 2 (rho = 0.34, p = 0.031), and beta 3 (rho = 0.38, p = 0.015) of the
ACC with a reduction of the Y-BOCS scores was identified. Our results suggest that
measuring brain activity with LORETA could be an efficient and applicable technique to
prospectively identify treatment responders in OCD.
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INTRODUCTION
Obsessive-compulsive disorder (OCD) has a life-time prevalence
of 0.8–2% and is characterized by the presence of obsessions
and/or compulsions (Baldwin et al., 2005). Patients suffering
from this disorder are best treated with a combination therapy
consisting of a selective serotonin reuptake inhibitor (SSRI) and
cognitive behavioral therapy (CBT), using exposure and response
prevention techniques. However, not all patients profit from
this treatment. Up to 30% of OCD patients treated with this
combination therapy show no or poor improvement after this
standard treatment (Ferguson, 2001). Differences of treatment
response suggest the existence of biological differences among
groups of OCD patients. Therefore, it would be desirable to
distinguish responders and non-responders before initiation of
the treatment course. The non-responder group could possibly
profit from early on augmentation treatment strategies and a
closer clinical monitoring. To date some studies have tried
to identify helpful tool for predicting therapy response in
OCD patients. One genome-wide association study indicated
suggestive roles of genes in the glutamatergic neurotransmission
and the serotonergic system as genetic predictors of treatment
response in the OCD patient cohort (Qin et al., 2015). Also,
longer duration of illness was found to be a significant predictor
of remission (Eisen et al., 2013). One PET imaging study showed
that a reduced regional cerebral blood flow in the orbitofrontal
cortex (OFC) and higher values in the posterior cingulate
cortex predicted better treatment response to fluvoxamine
(Rauch et al., 2002). However, studies investigating prognostic
biomarkers that are widely available and can be measured
before treatment are rare. One pilot study examined the
possibility of predicting treatment response in OCD patients with
low-resolution electromagnetic tomography and investigated
therefore 17 drug-free OCD patients. Over the course of a 12
week treatment with antidepressants (clomipramine, fluoxetine,
sertraline, paroxetine, imipramine, nortiptyline, venlafaxine,
and mirtazapine), LORETA values were calculated twice. The
17 patients were classified as responders and non-responders
according to a reduction of at least 35% in the YBOCS score.
The authors found that responders exhibited significantly lower
activities in the beta band in the rostral anterior cingulate and the
medial frontal gyrus (Fontenelle et al., 2006). Though the results
have to been seen as preliminary as the sample size was rather
small andOCDpatients did not have a standardized treatment. In
addition, functional imaging studies have revealed an abnormally
increased activity in the OFC, the basal ganglia and the anterior
cingulate cortex (ACC) in patients with OCD (Alptekin et al.,
2001; Lacerda et al., 2003), whereas successful pharmacological
or psychotherapeutic treatment of OCD patients was associated
with a reduction of aberrant activity in the OFC area (Aouizerate
et al., 2004).
The present study is based on the previously above
mentioned results mainly the findings from Fontenelle et al.
and aimed to further investigate whether Low-Resolution Brain
Electromagnetic Tomography (LORETA; Pascual-Marqui et al.,
1994), a three-dimensional EEG source localization technique,
could be a helpful tool to identify whether OCD patients that
show a clinical improvement over the course of treatment
compared to those patients who do not respond show differences
in LORETA values before and/or after standardized treatment. In
addition, the correlation between clinical treatment effects and
the electromagnetic tomography data was evaluated.
MATERIALS AND METHODS
Subjects
In total, forty-one patients with OCD (18 women, 23 men;
average age 34.5 years, SD: 9.8; mean duration of illness: 12.8
years, SD 9.3) participated in the study. All patients were
diagnosed according to DSM-IV and ICD-10. Symptom severity
was assessed using the Yale–Brown Obsessive–Compulsive Scale
(Y-BOCS; Goodman et al., 1989), where a score of at least 18
was required for inclusion. In addition, the Maudsley Obsessive–
Compulsive Scale (MOCI; Hodgson and Rachman, 1977) for
the assessment of OCD symptoms and the Hamilton Depression
Scale (HAMD-17; Hamilton, 1960) as well as the BeckDepression
Inventory (BDI; Beck et al., 1961) for the assessment of comorbid
depressive symptomatology were applied. Moreover, the State-
Trait Anxiety Inventory (STAI; Laux et al., 1981) was used
in order to assess state and trait anxiety in patients. Subjects
had to be free of comorbid psychiatric, neurological or severe
somatic diagnoses. All patients were either unmedicated or had
undergone a wash-out period of at least 2 weeks. The study
was reviewed and approved by the local ethics committee of
the Ludwig–Maximilians University and was carried out in
accordance with the Declaration of Helsinki. All subjects gave
written informed consent for participation in this study, after
design and procedures had been fully explained.
Study Design
A neurophysiological baseline recording of resting EEG was
performed in all patients. After this initial examination, patients
received for 10 weeks a combination therapy consisting of
an antidepressant and psychotherapy. All patients received the
selective serotonin reuptake inhibitor (SSRI) sertraline. The
initial dose was 50 mg/d for 4 weeks unchanged. Patients
that showed a reduction of <10% in the Y-BOCS score after
4 weeks on treatment received a dose augmentation to 100
mg/d sertraline and after 7 weeks an increase to 150 mg/d was
possible. In addition, all patients received semi-structured CBT
(with flooding, family and couple therapy) as an inpatient at
the Psychosomatic clinic Roseneck. At the end of the 10 week
treatment phase, a second EEG was performed in all study
participants. Treatment response was defined as a 50% or more
decrease in the Y-BOCS score after 10 weeks treatment with
sertraline and behavior therapy. The 50% reduction criterion
was chosen according to reports by Tolin et al. (2005) who
demonstrated that a Y-BOCS reduction of 40–50% may be
optimal for predicting mild illness or better at posttreatment
(CGI 3), and Lewin et al. (2011) who showed that a 35% Y-BOCS
reduction may be sufficient for clinical use, but for research 45%
or even 55% may be more efficient.
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EEG Data Acquisition and Loreta Analysis
For EEG recording, patients were seated in a sound-attenuated,
electrically shielded room in a reclining chair with eyes
closed (wakeful-resting condition). Electrodes were placed
via electrocaps (Electro-Cap International, Inc., Eaton, USA)
according to the 10/20 system with Cz as reference and Fpz as
ground electrode. Additional electrodes (above the left eye and at
the left ocular canthis) were used to record the electrooculogram
(EOG) simultaneously. Electrode skin impedance was <5 k
throughout the session. Data were collected with a sampling rate
of 250Hz and an analogous bandpass filter (0.16–50Hz). All
EEG recordings lasted 40min. Before analysis, artifact detection
was visually performed and additionally, the EEG was analyzed
four times independently by two experienced neurophysiologists.
When artifact detection was finished, segments with 2048ms
(512 data points) were chosen for further processing. A
priori it was determined that only subjects with at least
40 artifact-free epochs would be included. The analyses of
the frequency and localization were performed with the
LORETA (low resolution brain electromagnetic tomography)
software package (Pascual-Marqui et al., 1999). The following
(standard definitions) frequency bands of LORETA cross
spectrum analysis were identified for: delta (1.5–6.0Hz), theta
(6.5–8.0Hz, alpha1 (8.5–10.0Hz), alpha2 (10.5–12.0Hz), beta1
TABLE 1 | Descriptive socio-demographic data of responders and
non-responders.
Comparison of responders (n = 20) and non-responders (n = 21)
Responder Non-
responder
Significance
Age in years 35.0 (±8.8) 34.0 (±10.7) p = 0.758 t = 0.311
Age of disease onset 22.3 (±10.5) 21.2 (±8.3) p = 0.716 t = 0.367
Duration of illness 12.7 (±9.7) 12.8 (±9.0) p = 0.963 t = 0.047
Dose of sertraline (mg) 63.2 (±36.7) 61.9 (±21.8) p = 0.334 χ²= 2.191
Smoking status 5 smoker; 15
non-smoker
5 smoker; 16
non-smoker
p = 0.929 χ²= 0.008
Gender 9 female; 11
male
9 female; 12
male
p = 0.890 χ²= 0.190
(12.5–18.0Hz), beta2 (18.5–21.0Hz), and beta3 (21.5–30.0Hz).
The method LORETA assumes that the smoothest of all activity
distributions is most plausible (“smoothness assumption”) and
therefore, a particular current density distribution is found.
This fundamental assumption of LORETA directly relies on the
neurophysiological observation of coherent firing of neighboring
cortical neurons during stimulus processing (Pascual-Marqui
et al., 1994) and therefore can be seen as a physiologically based
constraint. However, this coherent firing has been described on
TABLE 3 | Differences of responders and non-responders at baseline and
follow-up.
Comparison of responders (n = 20) and non-responders (n = 21)
Responder Non-responder
BASELINE
Y-BOCS total score 25.15 (±6.21) 25.43 (±5.49) p = 0.880 t = 0.15
Y-BOCS compulsions 11.80 (±4.20) 11.86 (±3.47) p = 0.962 t = 0.05
Y-BOCS obsessive
thoughts
13.35 (±2.96) 13.57 (±2.64) p = 0.802 t = 0.25
HAMD-17 13.90 (±6.55) 11.65 (±5.53) p = 0.248 t = 1.18
MOCI 12.61 (±4.63) 13.83 (±3.92) p = 0.399 t = 0.86
BDI 15.21 (±8.31) 19.44 (±8.73) p = 0.140 t = 1.51
AFTER 10 WEEKS TREATMENT
Y-BOCS total score 8.30 (±4.04) 20.29 (±6.09) p = 0.000 t = 7.39
Y-BOCS compulsions 3.90 (±2.17) 9.43 (±3.71) p = 0.000 t = 5.86
Y-BOCS obsessive
thoughts
4.40 (±2.44) 10.86 (±2.94) p = 0.000 t = 7.64
HAMD-17 8.30 (±7.40) 10.00 (±6.85) p = 0.456 t = 0.75
MOCI 7.06 (±5.18) 11.18 (±6.17) p = 0.043 t = 2.11
BDI 10.11 (±12.37) 17.78 (±12.17) p = 0.069 t = 1.88
DIFFERENCE BASELINE—WEEK 10
Y-BOCS total score 16.85 (±5.82) 5.14 (±4.91) p = 0.000 t = 6.97
Y-BOCS compulsions 7.90 (±3.60) 2.43 (±3.14) p = 0.000 t = 5.20
Y-BOCS obsessive
thoughts
8.95 (±3.52) 2.71 (±2.76) p = 0.000 t = 6.33
HAMD-17 5.60 (±5.69) 1.47 (±7.53) p = 0.063 t = 1.92
MOCI 5.93 (±5.42) 2.87 (±2.75) p = 0.064 t = 1.96
BDI 5.71 (±11.37) 2.65 (±8.62) p = 0.384 t = 0.88
TABLE 2 | Descriptive psychopathology of the patients at baseline and follow-up.
Patients with OCD (n = 41)
Baseline mean
(sd)
After 10 weeks
treatment mean (sd)
Delta (sd) Significance
Y-BOCS total score 25.29 (±5.78) 14.44 (±7.94) 10.85 (±7.96) p = 0.000 t = 8.74
Y-BOCS sub score
(compulsions)
11.83 (±3.79) 6.73 (±4.12) 5.10 (±4.33) p = 0.000 t = 7.54
Y-BOCS sub score
(obsessive thoughts)
13.46 (±2.77) 7.71 (±4.22) 5.76 (±4.43) p = 0.000 t = 8.32
HAMD-17 12.78 (±6.08) 9.15 (±7.09) 3.59 (±6.89) p = 0.002 t = 3.26
BDI 17.27 (±8.67) 13.94 (±12.70) 4.18 (±10.06) p = 0.002 t = 2.42
MOCI 13.20 (±4.16) 8.80 (±5.56) 4.40 (±4.50) p = 0.000 t = 5.36
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the level of cortical columns, which have amuch smaller diameter
than the voxels used in the LORETA software; the empirical basis
for coherent firing in themillimeter range is not strong enough to
fully accept this constraint as a physiological one, even if it might
help to produce useful results. While for typical scalp-potentials,
coherent firing might be observed in brain volumes as large as
or even larger than LORETA voxels. Therefore, the resulting
solution is characterized by its relatively low spatial resolution,
which is a direct consequence of the smoothness constraint.
Taken this together, the solution produces a “blurred-localized”
image of a point source, conserving the location of maximal
activity, but with a certain degree of dispersion. In the present
study, the version of LORETA used is the digitized Talairach
atlas available as digitized MRI from the Brain Imaging Centre,
Montreal Neurologic Institute, estimating the current source
density (microAmperes/mm2) distribution for either single time
points or epochs of brain electric activity on a dense grid of
2394 voxels at 7mm spatial resolution (Pascual-Marqui et al.,
1999). The solution space (the three-dimensional space where the
inverse EEG problem is solved) was restricted to the gray matter
and hippocampus in the Talairach atlas (anatomically based
constraint). Localization with regard to spherical and realistic
head geometry was done using EEG electrode coordinates
reported by Towle et al. (1993).
Statistical Analyses
EEG frequency bands included in the analyses of delta
(1.5–6.0Hz), theta (6.5–8.0Hz), alpha 1 (8.5–10Hz), alpha 2
(10.5–12.0Hz), beta 1 (12.5–18.0Hz), beta 2 (18.5–21.0Hz),
and beta 3 (21.5–30.0Hz). For the assessment of treatment
effects in OCD patients, a region of interest (ROI) approach
was defined as follows: 1. ACC: anterior cingular cortex and 2.
OFC: orbito-frontal cortex. These regions were chosen because
these have been previously identified with altered activity and
response to antidepressant treatment (Fontenelle et al., 2006;
Mulert et al., 2007; Schiepek et al., 2007). The first ROI ACC
consisted of 25 voxel from the Brodmann areas 24, 25, and 32
and also the Talairach from x = −10 to 11, from y = 3 to
45 and from z= −6 to 8. The second ROI OFC consists of
298 voxel from the Brodmann areas 10, 11, 25, and 47 and
also the Talairach from x= −45 to 52, from y = 9 to 65 and
from z= −25 to 24.
In order to evaluate group differences between responders
and non-responders in regard to age, age of disease onset,
gender and data about the psychopathology unpaired t-test
for independent samples was used. Spearman’s correlation
coefficients were calculated to relate the measured LORETA
current density changes in the defined ROIs vs. the reduction of
Y-BOCS scores. In addition, linear as well as robust regression
techniques were used to assess the association between density
changes and the reduction of Y-BOCS. Huber type M-estimation
(Huber and Ronchetti, 1981) as implemented in the R package
MASS (Venables and Ripley, 2002; function rlm) was used
to down-weight observations with extreme density changes.
As further robust technique, which also takes outliers in Y-
BOCS scores and leverage points into account, we used MM-
estimation (Yohai et al., 1991;Marazzi, 1993; function rlm) which
combines M-estimation with the resistance of high breakdown
estimators. Approximate p-values based on the assumption
that the t statistics [estimate/SE(estimate)] are approximately
normally distributed were obtained for M-estimators and MM-
estimators. Given the exploratory character of the study,
statistical significance levels were set to p < 0.05 and p < 0.10
(statistical trend) and not additionally corrected for multiple
comparisons. Statistical analyses were performed using the SPSS
software (IBM SPSS, Version 23.0), the statistical software R
(version 3.0.1; Team, 2013) or with the implemented LORETA
analysis tool that includes a correction for multiple comparisons
and does not require any assumption of Gaussianity (Diener
et al., 2010). The localization of the differences in activity between
the groups of responders and non-responders was assessed by
voxel-by-voxel non-paired t-test of the LORETA images, based
on the power of estimated electric current density, which results
in t statistic three dimensional images (Mientus et al., 2002). In
these images, cortical voxels of statistically significant differences
were identified by a non-parametric approach (maximum t-
statistic) using randomization strategy that determined the
critical probability threshold values for actually observed statistic
with corrections for multiple testing (Holmes et al., 1996).
RESULTS
All OCD Patients Compared at Baseline
and Follow-Up
Descriptive Clinical Data
Sociodemographic data was compared between the groups of
responders and non-responders and no statistical differences
were identified. Data concerning the psychopathology of the
patients showed a significant reduction over the course of the
therapy in all rating scales. After 10 weeks of treatment, 20 of 41
patients fulfilled the criteria for treatment response, defined as a
decrease in the Y-BOCS score by at least 50%, see also Tables 1–3
for detailed results.
EEG Data
The distribution of EEG frequency bands is shown in Tables 4–7
and Figure 1 for baseline and follow-up and also the comparison
of the responders and non-responders (OFC and ACC region)
are displayed.
Responders Compared at Baseline and
Follow-Up
When the time points at baseline and follow-up were compared,
responders exhibited significantly lower brain electrical resting
activity in the LORETA analyses in the beta 1 (12.5–18.0Hz;
t = 3.17. p < 0.05) and beta 3 (21.5–30.0Hz; t = 3.11. p < 0.05)
frequency band, especially in the pre- and postcentral gyri of the
frontal and parietal lobe. This indicates an increase in activity
over the course of treatment. Results are shown in Table 8 and
Figures 2A,B.
Within the ROI analysis of the brain area OFC responders
exhibited a significantly lower brain electrical resting activity in
the alpha 2 (10.5–12.0Hz; t = 2.15. p < 0.05) frequency band
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TABLE 4 | Frequency bands of the ACC.
Frequency bands
(in 10−3 µV2)
alpha1
T0
alpha1
T1
alpha2
T0
alpha2
T1
beta1
T0
beta1
T1
beta2
T0
beta2
T1
beta3
T0
beta3
T1
delta
T0
delta
T1
theta
T0
theta
T1
Non-responder Mean 0.049 0.043 0.107 0.099 0.060 0.061 0.177 0.220 1.306 1.218 0.738 0.526 0.079 0.068
n 21 21 21 21 21 21 21 21 21 21 21 21 21 21
sd 0.0412 0.0363 0.0755 0.0921 0.0522 0.0769 0.1481 0.3323 0.8993 1.0182 0.6295 0.3232 0.0664 0.0574
Minimum 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.3 0.2 0.2 0.0 0.0
Maximum 0.2 0.1 0.3 0.4 0.2 0.3 0.6 1.6 3.5 4.9 2.6 1.4 0.2 0.2
Responder Mean 0.049 0.068 0.067 0.091 0.034 0.042 0.101 0.122 0.980 2.032 0.552 1.633 0.088 0.087
n 20 20 20 20 20 20 20 20 20 20 20 20 20 20
sd 0.0543 0.0816 0.0459 0.0599 0.0217 0.0248 0.0840 0.0765 0.6675 3.5464 0.4261 3.2201 0.0908 0.0716
Minimum 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.1 0.2 0.0 0.0
Maximum 0.2 0.3 0.2 0.3 0.1 0.1 0.4 0.3 3.0 16.0 1.6 014.5 0.4 0.3
All patients Mean 0.049 0.055 0.087 0.095 0.047 0.051 0.140 0.172 1.147 1.615 0.647 1.066 0.083 0.077
n 41 41 41 41 41 41 41 41 41 41 41 41 41 41
sd 0.0474 0.0631 0.0653 0.0773 0.0419 0.0579 0.1257 0.2460 0.8020 2.5810 0.5415 2.3002 0.0783 0.0647
Minimum 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.1 0.2 0.0 0.0
Maximum 0.2 0.3 0.3 0.4 0.2 0.3 0.6 1.6 3.5 16.0 2.6 0.4.5 0.4 0.3
Descriptive data about the frequency bands of the ACC region. T0 are baseline values and T1 are values after 10 weeks of treatment in µV2. n, number of patients; sd, standard
deviation.
TABLE 5 | Frequency bands of the OFC.
Frequency bands
(in 10−3 µV2)
alpha1
T0
alpha1
T1
alpha2
T0
alpha2
T1
beta1
T0
beta1
T1
beta2
T0
beta2
T1
beta3
T0
beta3
T1
delta
T0
delta
T1
theta
T0
theta
T1
Non-responder Mean 0.052 0.044 0.130 0.111 0.074 0.073 0.214 0.243 1.275 1073 0.641 0.476 0.076 0.057
n 21 21 21 21 21 21 21 21 21 21 21 21 21 21
sd 0.0510 0.0464 0.1035 0.1073 0.0725 0.1059 0.2016 0.3661 1.1111 0.9726 0.8012 0.3530 0.0787 0.0518
Minimum 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.1 0.1 0.0 0.0
Maximum 0.2 0.2 0.4 0.4 0.3 0.5 0.9 1.7 5.1 4.7 3.9 1.4 0.3 0.2
Responder Mean 0.042 0.059 0.062 0.099 0.033 0.047 0.098 0.140 0.826 1.974 0.452 1.453 0.068 0.073
n 20 20 20 20 20 20 20 20 20 20 20 20 20 20
sd 0.0453 0.0576 0.0406 0.0737 0.0204 0.0317 0.0765 0.0999 0.5289 3.3293 0.3307 3.0294 0.0672 0.0588
Minimum 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.4 0.2 0.2 0.0 0.0
Maximum 0.2 0.2 0.2 0.3 0.1 0.1 0.3 0.4 2.4 14.3 1.3 12.9 0.3 0.2
All patients Mean 0.047 0.051 0.097 0.105 0.054 0.060 0.157 0.193 1.056 1.513 0.549 0.953 0.072 0.065
n 41 41 41 41 41 41 41 41 41 41 41 41 41 41
sd 0.0480 0.0520 0.0856 0.0915 0.0571 0.0792 0.1631 0.2728 0.8955 2.4384 0.6182 2.1600 0.0725 0.0553
Minimum 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.1 0.1 0.0 0.0
Maximum 0.2 0.2 0.4 0.4 0.3 0.5 0.9 1.7 5.1 14.3 3.9 12.9 0.3 0.2
Descriptive data about the frequency bands of the OFC region. T0 are baseline values and T1 are values after 10 weeks of treatment in µV2. n, number of patients; sd, standard
deviation.
where time points before and after treatment were compared.
For the frequency bands alpha 1 (8.5–10.0Hz; t = 2.05.
p < 0.10) and beta 1 (12.5–18.0Hz; t = 1.80. p < 0.10)
a trend toward a reduced activity was evaluated. In addition,
ROI analysis of the area ACC revealed a trend toward a
reduced activity in the frequency band alpha 1 (8.5–10.0Hz;
t = 1.77. p < 0.10) when baseline was compared to
follow-up.
Non-Responders Compared at Baseline
and Follow-Up
For the patient group of the non-responders a significantly
higher brain electrical resting activity according to the LORETA
analysis could be shown in the beta 1 (12.5–18.0Hz; t = 3.11.
p < 0.05) frequency band when baseline was compared to
follow-up, indicating that brain activity decreased over the course
of treatment. A similar trend toward a higher activity in the
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TABLE 6 | Changes of the frequency bands of the ACC.
Changes in the frequency bands
(in 10−3 µV2)
alpha1
T1–T0
alpha 2
T1–T0
beta 1
T1–T0
beta 2
T1–T0
beta 3
T1–T0
delta
T1–T0
theta
T1–T0
Non-responder Mean −0.006 −0.064 0.001 0.044 −0.087 −0.211 0.000
n 21 21 21 21 21 21 21
sd 0.0270 0.0624 0.0581 0.2835 0.9188 0.7525 0.0400
Minimum −0.1 −0.2 −0.1 −0.2 −2.3 −2.0 0.0
Maximum 0.1 0.0 0.2 1.2 2.8 1.0 0.0
Responder Mean 0.019 0.001 0.007 0.021 1.052 1.080 0.000
n 20 20 20 20 20 20 20
sd 0.0475 0.0688 0.0280 0.1024 3.3387 3.2735 0.0800
Minimum −0.1 −0.1 0.0 −0.2 −0.2 −0.7 0.0
Maximum 0.2 0.2 0.1 0.2 0.2 14.2 0.0
All patients Mean 0.006 −0.032 0.004 0.033 0.469 0.419 0.000
n 41 41 41 41 41 41 41
sd 0.0399 0.0725 0.0455 0.2128 2.4596 2.4086 0.06
Minimum −0.1 −0.2 −0.1 −0.2 −2.3 −2.0 0.0
Maximum 0.2 0.2 0.2 1.2 14.0 14.2 0.0
TABLE 7 | Changes of the frequency bands of the OFC.
Changes in the frequency bands
(in 10−3 µV2)
alpha1
T1–T0
alpha 2
T1–T0
beta 1
T1–T0
beta 2
T1–T0
beta 3
T1–T0
delta
T1–T0
theta
T1–T0
Non-responder Mean –0.007 –0.019 0.001 0.000 –0.202 –0.165 –0.019
n 21 21 21 21 21 21 21
sd 0.0450 0.0928 0.0965 0.3400 1.1531 0.7782 0.0724
Minimum –0.1 –0.2 –0.1 0.0 –3.9 –3.3 –0.3
Maximum 0.1 0.3 0.4 0.0 2.9 0.7 0.1
Responder Mean 0.017 0.037 0.013 0.000 1.148 1.001 0.005
n 20 20 20 20 20 20 20
sd 0.0393 0.0776 0.0342 0.1200 3.1715 3.0062 0.0626
Minimum 0.0 –0.1 0.0 0.0 –1.4 –0.7 –0.2
Maximum 0.1 0.2 0.1 0.0 12.5 12.2 0.1
All patients Mean 0.005 0.008 0.006 0.000 0.456 0.404 0.007
n 41 41 41 41 41 41 41
sd 0.0436 0.0893 0.0726 2.4309 2.4309 2.2235 0.0681
Minimum –0.1 –0.2 –0.1 0.0 –3.9 –3.3 –0.3
Maximum 0.1 0.3 0.4 0.0 12.5 12.2 0.1
non-responder group was detected for the frequency bands alpha
1 (8.5–10.0Hz; t = 2.90. p < 0.10), alpha 2 (10.5–12.0Hz;
t = 2.92. p < 0.10) and beta 2 (18.5–21.0Hz; t = 2.73.
p < 0.10). Over the course of treatment the activity diminished.
In the ROI analysis no significant differences were found for
the non-responder group. Table 9 shows the significant results
and Figures 3A,B displays the current density of the LORETA
analysis for beta 1.
Responders vs. Non-Responders at
Baseline
Responders were compared to non-responders before therapy
at baseline, where a significant hypoactivity for responders was
found in the LORETA analyses in the frequency bands beta 1
(12.5–18.0Hz; t = 2.86, p < 0.05), beta 2 (18.5–21.0Hz; t =
2.81, p < 0.05) and beta 3 (21.5–30.0Hz; t = 2.76, p < 0.05).
Precisely, the brain regions that were affected by the hypoactivity
were for beta 1 the medial/superior frontal gyrus (12 voxels, BA
9/10, p < 0.05, t-values between −2.90 and −3.31) and the
inferior frontal gyrus, precentral gyrus (5 voxels, BA 44, p < 0.05,
t = −3.31). For beta 2 the medial/superior frontal gyrus (9
voxels, BA 10, p < 0.05, t-values between −2.88 and 3.03) and
medial/inferior temporal gyrus (4 voxels, BA 20, 21, p < 0.05,
t = 3.01) and precentral gyrus (3 voxels, BA 6, p < 0.05,
t = 3.29). And for beta 3 the medial/superior frontal gyrus
(BA 10, p < 0.05, 13 voxels, t-values between 2.80 and −3.04)
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FIGURE 1 | Descriptive data of EEG frequency bands. Mean values of all measured EEG frequency bands (inµAmpere/mm2 ) are shown at baseline and at
follow-up. (A) brain region ACC; (B) brain region OFC.
TABLE 8 | Characteristics of LORETA current density differences for
responders at baseline and follow-up.
Frequency
band
Talairach
coordinates
t-value
(significance)
Anatomy
X Y Z
beta 1 −45 24 22 3.40 (p < 0.05) BA 46 (medial frontal gyrus)
−52 24 29 3.40 (p < 0.05) BA 46 (medial frontal gyrus)
−45 24 29 3.40 (p < 0.05) BA 46 (medial frontal gyrus)
−24 45 29 3.18 (p < 0.05) BA 10 (superior frontal gyrus)
−31 52 29 3.18 (p < 0.05) BA 10 (superior frontal gyrus)
beta 3 −31 −18 −34 3.22 (p < 0.05) BA 20 (uncus. Limbic cortices)
−31 −11 −27 3.22 (p < 0.05) BA 20 (uncus. Limbic cortices)
−31 −18 −27 3.22 (p < 0.05) BA 36 (parahippocampal gyrus)
BA, Brodmann area.
and fusiform gyrus (BA 20/37, 21 voxels, p < 0.05, t-values
between−2.97 and−4.06) and parahippocampal gyrus (5 voxels,
p < 0.05, t-values between−2.97 and−4.33) andmedial/inferior
temporal gyrus (BA 37, 6 voxels, p < 0.05, t-values between
−3.00 and −4.06) were identified. Figures 4A,B summarize the
results.
The ROI analysis revealed that the area ACC shows a
significantly reduced activity of the responders in comparison
to non-responders in the frequency band alpha 2 (10.5–12.0Hz;
t = 2.06, p < 0.05) at baseline. Additionally, a trend toward a
reduced activity was found for beta 1 (12.5–18.0Hz; t = 2.06, p =
0.05) and beta 2 (18.5–21.0Hz; t = 2.04, p = 0.05). The other
investigated area OFC had also a reduced activity for the group of
responders compared to non-responders in the frequency bands
alpha 2 (10.5–12.0Hz; t = 2.81, p < 0.01), beta 1 (12.5–18.0Hz;
t = 2.50, p < 0.05) and beta 2 (18.5–21.0Hz; t = 2.50, p < 0.05)
at baseline.
Responders vs. Non-Responders at
Follow-Up
The two groups of responders and non-responders did not show
significant differences with regard to LORETA and ROI analyses
after 10 weeks at follow-up.
Correlation of the Psychopathology with
Electrophysiological Data
The psychopathology of the OCD patients measured with the aid
of Y-BOCS was correlated with the brain activity of the ROI areas
OFC and ACC at baseline and follow-up. The activity change
was defined as: brain activity after 10 weeks of treatment minus
activity at baseline. Using Spearman’s correlation coefficient a
positive correlation between the brain activity change in the area
ROI OFC and the reduction of the Y-BOCS scores was identified
for the frequency bands alpha 2 (rho = 0.40, p = 0.010), beta
3 (rho = 0.42, p = 0.006), delta (rho = 0.33, p = 0.038), theta
(rho = 0.34, p = 0.031), alpha 1 (rho = 0.38, p = 0.015), and
beta1 (rho= 0.34, p = 0.028).
Since the data contains many outliers, linear regression was
not appropriate and robust regression techniques were applied.
Figure 5 shows the regression lines obtained by Huber-type
M-estimation (dotted line) and MM-estimation (dashed line).
In addition, the regression line of the classical least squares
fit is shown (solid line) to assess the influence of outlying
observations. For five of six frequency bands the slope of
the least squares regression line is larger than that of the
robust techniques, indicating that the outlying observations
induce a larger correlation between psychopathology and
electrophysiological data. The approximate p-values for testing
the regression coefficients obtained through M-estimation or
MM-estimation are very small (Table 10), indicating that there
is an association even after taking outliers and influential points
into account.
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FIGURE 2 | (A) LORETA images for responders at baseline and follow-up: Images on top show voxel-wise current density differences in the frequency band beta 1 for
responders at baseline compared to follow-up. In the bottom line the same is shown for the frequency band beta 3. The blue color indicates a statistical significant
effect (images in the top line: tmax = −3.40, xyz = −45, 24, 22, p < 0.05 and bottom line: tmax = −3.22, xyz = −31, −18, −34) of reduced current density in the
MNI-MRI-standard space. (B) Corresponding color bar.
TABLE 9 | Characteristics of LORETA current density differences for
non-responders.
Frequency
band
Talairach
coordinates
t-value
(significance)
Anatomy
X Y Z
beta 1 39 10 −6 3.20 (p < 0.05) BA 13 (sub-lobar)
BA, Brodmann area.
Furthermore, the brain activity of the other region ACC
was correlated with the psychopathology of the OCD patients
measured with Y-BOCS at baseline and follow-up. Again, the
activity change was as explained above, and a positive correlation
between the brain activity in the ROI ACC and the reduction
of Y-BOCS scores was identified using Spearman’s correlation
coefficient. The frequency bands delta (rho = 0.33, p = 0.035),
alpha 1 (rho= 0.36, p = 0.019), alpha 2 (rho= 0.34, p = 0.031),
and beta 3 (rho = 0.38, p = 0.015) are shown in Figure 6.
Also shown are the regression lines for the least squares fit and
the robust regression methods. The findings are very similar to
those for the ROI area OFC: outlying observations induce a larger
correlation between psychopathology and electrophysiological
data since the robust regression methods yield less steep
regression lines. Approximate p-values are shown in Table 11.
DISCUSSION
The present study aimed to identify possible predictors of
treatment response in patients suffering from OCD. We
found that treatment responders exhibited already at baseline
significantly lower brain electrical activity in higher frequency
bands compared to non-responders and these findings were
confirmed with ROI analyses that also revealed a significantly
lower brain electrical resting activity in the ACC of responders.
Over a 10 week course of treatment, the responder group had
an increase in brain electric activity from baseline to follow-
up, confirmed by LORETA analyses showing significantly lower
brain electrical activity in the beta frequency bands, the same
was true for the ROI analysis of the OFC brain area of
responders. In addition, the group of non-responders exhibited
the opposite findings: These OCD patients had a significantly
higher brain electrical resting activity in the beta frequency band
when baseline was compared to follow-up. The presented data
clearly indicate that the brain activity increases in responders,
whereas in non-responders brain activity decreases over the
course of treatment. Therefore, the collection of electromagnetic
tomography data might eventually help to distinguish between
OCD patients who will respond to treatment and those who do
not respond already before the onset of therapy.
Regarding lower electrical activity in responders to OCD
treatment our results are consistent with those of previous
studies: In particular, one pilot study found that lower
pretreatment activity in the beta band within the rostral anterior
cingulate and the medial frontal gyrus was associated with a
better therapeutic response (Fontenelle et al., 2006). Based on
these preliminary data, our group has replicated these findings
on a larger OCD patient sample with stricter response criteria:
We chose a reduction of at least 50% of the YBOCS score
instead of 35%. In addition a standardized treatment with only
one antidepressant (sertraline) was determined, and further
investigations of electrical resting activity at different time points
as well as correlations of the psychopathology with these data
were added.
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FIGURE 3 | (A) LORETA images for non-responders at baseline compared to follow-up: voxel-wise current density differences in the frequency band beta 1 for
non-responders. Red areas represent brain regions showing significantly higher activity at baseline compared to follow-up. The red color indicates a statistical
significant effect (tmax = 3.20, xyz = 39, 10, −6 p < 0.05) of reduced current density in the MNI-MRI-standard space. (B) Corresponding color bar.
FIGURE 4 | (A) LORETA images for responders vs. non-responders at baseline: Images on top show voxel-wise current density differences in the frequency band
beta 1 at baseline. The middle line contains the frequency band beta 2, in the bottom line the same is shown for the frequency band beta 3. Blue areas represent brain
regions showing significantly lower LORETA values at baseline. The blue color indicates a statistical significant effect (images in the top line: tmax = −3.31, xyz = −52,
17, 8 p < 0.05; middle line: tmax = −3.29, xyz = −59, −4, 22 and bottom line: tmax = −4.33, xyz = −38, −18, −27) of reduced current density in the
MNI-MRI-standard space. (B) Corresponding color bar.
In order to address the question whether psychopathology
of OCD was associated with brain activity, OCD symptom
severity—assessed with the aid of Y-BOCS—was correlated with
ROI analyses. A positive correlation between frequency bands
of both brain areas, the ROI OFC and the ROI ACC, with
a reduction of Y-BOCS scores was identified. These findings
indicate that an improvement of OCD symptoms is associated
with an altered brain activity. In a previous study our research
group has already identified evidence for symptom-related
electrophysiological alterations in unmedicated patients with
OCD. It has been shown that patients presenting with high
levels of obsessions had higher absolute EEG power measures,
especially for the faster frequencies, whereas patients with
high compulsion scores were likely to have lower absolute
EEG power, especially of slower frequencies (Andreou et al.,
2013).
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FIGURE 5 | Correlations between the psychopathology [reductions of Y-BOCS scores (%)] and the change in frequency bands (time point 10 weeks
minus baseline) in the OFC. Frequency band alpha 2, beta3, theta, delta, alpha 1, and beta 1 are shown (inµAmpere/mm2 ) and regression lines obtained through
M-estimation, MM-estimation and the least squares method.
TABLE 10 | Estimated regression coefficients from robust regression (M-estimation and MM-estimation), corresponding t-values and approximate
p-values for OFC.
Regression coefficient M-estimation
in 10−7
Regression coefficient MM-estimation
in 10−7
t-value (p-value)
M-estimation
t-value (p-value)
MM-estimation
alpha 2 6.05 4.33 2.18 (p = 0.0357) 1.88 (p = 0.0683)
beta 3 74.10 45.00 2.76 (p = 0.0088) 1.93 (p = 0.0603)
theta 3.46 2.32 2.19 (p = 0.0344) 1.73 (p = 0.0912)
delta 43.10 16.70 2.18 (p = 0.0351) 0.92 (p = 0.3607)
alpha 1 1.67 0.505 1.94 (p = 0.0592) 0.73 (p = 0.4717)
beta 1 3.27 3.04 1.99 (p = 0.0539) 1.81 (p = 0.0784)
T-values are computed as t = estimate/SE(estimate) and p-values are obtained using the Wald test.frequency band.
Also, a previous PET study investigated the correlation
between symptomatology of OCD and brain activity and
showed that in medicated OCD patients, the decrease in
right orbitofrontal metabolism was directly correlated with two
measures of OCD improvement (Swedo et al., 1992), indicating
that brain activity and OCD psychopathology are mutually
dependent parameters.
In our study, the investigated brain areas ACC and OFC
had already been linked to an abnormal activity in OCD
patients and were therefore proposed to play a role in the
pathophysiology of the disease. However, other brain regions
like the dorsolateral prefontal cortex and the inferior frontal
gyrus that have previously shown abnormalities in OCD patients
(Goncalves et al., 2015; Tang et al., 2015) have not been
investigated in our study. Andreou et al. have examined brain
activity distribution with LORETA and reported an increased
P300-related activity predominantly in the left OFC, but also
in left prefrontal, parietal and temporal areas in OCD patients
compared to controls (Andreou et al., 2013). Moreover, especially
the beta frequency bands have already been shown to have
a lower power also in the frontal brain regions (Kuskowski
et al., 1993). For the other investigated region ACC, LORETA
analyses revealed an excess current source density in the beta
frequencies in the cingulate gyrus in OCD patients compared
to controls (Sherlin and Congedo, 2005). Also fMRI studies
strengthen the evidence for ACC dysfunction in OCD (Brennan
et al., 2015). In addition, another LORETA study in OCD
patients has shown that there are differences in the frequency
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FIGURE 6 | Correlations between the psychopathology [reduction of Y-BOCS scores (%)] and the change in frequency bands (time point 10 weeks
minus baseline) in the ACC. Frequency bands alpha 2, beta3, theta, delta, alpha 1, and beta 1 are shown (inµAmpere/mm2 ) and regression lines obtained through
M-estimation, MM-estimation and the least squares method.
TABLE 11 | Estimated regression coefficients from robust regression (M-estimation and MM-estimation), corresponding t-values and approximate
p-values for ACC.
Regression coefficient M-estimation
in 10−7
Regression coefficient MM-estimation
in 10−7
t-value (p-value)
M-estimation
t-value (p-value)
MM-estimation
alpha 2 6.98 5.37 2.56 (p = 0.0144) 2.11 (p = 0.0410)
beta 3 70.60 54.80 2.49 (p = 0.0173) 2.05 (p = 0.0473)
theta 2.72 2.02 1.73 (p = 0.0910) 1.25 (p = 0.2205)
delta 62.206 42.50 1.48 (p = 0.1460) 1.06 (p = 0.2945)
alpha 1 2.25 1.32 2.09 (p = 0.0435) 1.64 (p = 0.1098)
beta 1 1.59 1.40 1.36 (p = 0.1812) 1.15 (p = 0.2574)
T-values are computed as t = estimate/SE(estimate) and p-values are obtained using the Wald test.frequency band.
bands between patients and controls. The authors found that
OCD patients had an increased current density for beta in the
frontal, parietal and limbic lobes (Velikova et al., 2010). However,
our data are difficult to compare to studies investigating OCD
patients in comparison to healthy controls, since we looked
only at OCD patients. Still, our findings that patients who are
going to be treatment responders have lower activation levels
in relevant brain areas may point toward a rather normal brain
activity level, possibly making them more likely to respond to
treatment.
The present study has several strengths and limitations.
Regarding its strength our study has a comparatively large patient
sample with a homogenous standardized treatment for all OCD
patients. With the criteria of response chosen at the level of at
least 50% reduction in the Y-BOCS, these rather strict response
criteria identified only responders who really had a clinically
significant improvement of their OCD symptoms. In terms of
limitations, all our patients were only unmedicated and not
drug naïve. Furthermore, in this study no testing for multiple
comparisons was done due to the exploratory character of the
study. Therefore, based on the findings by Fontenelle et al.
(2006) our results can only be seen as the next step toward
the clinical applicability of predictive electromagnetical markers
in OCD patients. However, the final clinical implementation of
EEG markers in OCD cannot yet be reached with the present
results.
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Some authors have suggested that an increase in brain activity
is due to an improvement of depressive symptoms (Kennedy
et al., 2001). However, our sample of OCD patients did not
distinguish between groups of responders and non-responders
with regard to depressive symptoms. Study participants had a
mean HAMD-17 score of 12.78 indicating only mild depressive
symptoms (cut-off HAMD-17; Zimmerman et al., 2013) before
treatment, and a score of 9.15 after treatment. Responders
and non-responders did not show a significant difference
regarding HAMD-17 or BDI scores for depressive symptoms.
Therefore, a contamination of our results caused by the influence
of depressive symptoms seems unlikely in our investigated
sample.
It would also be of interest to link our data to research
on brain connectivity in order to broaden the picture of
OCD psychopathology. Consistent with neurobiological models
of OCD, OFC, and basal ganglia have been identified to be
hyperconnected in unmedicated patients, and antidepressant
medication may reduce connectivity within corticobasal ganglia-
thalamo-cortical circuits in OCD (Beucke et al., 2013). Also, an
altered global brain connectivity in dorsal and ventral striatum of
OCD patients has been shown, as well as complex disturbances
in PFC networks which could contribute to disrupted cortical-
striatal-cerebellar circuits in OCD (Anticevic et al., 2014).
Altogether, our results suggest that measuring brain activity
with LORETA could eventually be an efficient and simple
technique in order to identify OCD patients likely to respond
to treatment. We hope that future studies will continue to
rigorously examine whether the biomarkers we have shown in the
present study might qualify as an effective predictor of treatment
response in OCD patients. More generally, our findings illustrate
the potential utility of resting EEG and LORETA analyses for
identifying biomarkers of treatment response, thereby facilitating
a personalized clinical approach to treating patients suffering
from OCD.
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